Related references
Note: Only part of the references are listed.The role of p53 in anti-tumor immunity and response to immunotherapy
Lindsey Carlsen et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2023)
Vaccination against Her-2/neu, with focus on peptide-based vaccines
J. Tobias et al.
ESMO OPEN (2022)
Vaccination with a shared oncogenic tumor-self antigen elicits a population of CD8+T cells with a regulatory phenotype
C. Riccay Elizondo et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)
Clinical and Immunological Effects of p53-Targeting Vaccines
Shan Zhou et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Brain Tumor Vaccines
Justin Lee et al.
NEUROSURGERY CLINICS OF NORTH AMERICA (2021)
Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential
Espen Basmo Ellingsen et al.
FRONTIERS IN IMMUNOLOGY (2021)
Analysis of the CD8+IL-10+T cell response elicited by vaccination with the oncogenic tumor-self protein D52
C. Riccay Elizondo et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Cancer Neoantigens
Ton N. Schumacher et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 37, 2019 (2019)
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
Alberto A. Chiappori et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Improving vaccine efficacy against malignant glioma
Erik Ladomersky et al.
ONCOIMMUNOLOGY (2016)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes
Keely M. McNamara et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
AR function in promoting metastatic prostate cancer
Michael A. Augello et al.
CANCER AND METASTASIS REVIEWS (2014)
TPD52 Represents a Survival Factor in ERBB2-Amplified Breast Cancer Cells
Nuruliza Roslan et al.
MOLECULAR CARCINOGENESIS (2014)
Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?
Jennifer A. Byrne et al.
TUMOR BIOLOGY (2014)
Overexpressed oncogenic tumor-self antigens New vaccine targets
Robert K. Bright et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines
Ursula Wiedermann et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Genetic markers associated with early cancer-specific mortality following prostatectomy
Wennuan Liu et al.
CANCER (2013)
The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer
Brian M. Olson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients
Hidekazu Kameshima et al.
CANCER SCIENCE (2013)
Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: A phase I/II clinical trial
Eliane C. M. Zeestraten et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy
Jacky T. Yeung et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Beyond the Standard of Care: A Review of Novel Immunotherapy Trials for the Treatment of Lung Cancer
Richard D. Hall et al.
CANCER CONTROL (2013)
Roles of EphA2 in Development and Disease
Jeong Eun Park et al.
GENES (2013)
Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen
Jennifer D. Bright et al.
ONCOIMMUNOLOGY (2013)
Selection of Self-Reactive T Cells in the Thymus
Gretta L. Stritesky et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001
Eleni-Kyriaki Vetsika et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
Osama E. Rahma et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma
Juergen C. Becker et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I-Modified Peptides
Paola Filipazzi et al.
CLINICAL CANCER RESEARCH (2012)
Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer
Ninke Leffers et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial
Paal Fr. Brunsvig et al.
CLINICAL CANCER RESEARCH (2011)
Induction of CD8+ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
Hideho Okada et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
HER-2/neu as a target for cancer vaccines
Constantin N. Baxevanis et al.
IMMUNOTHERAPY (2010)
Proteomic characterization of Her2/neu-overexpressing breast cancer cells
Hexin Chen et al.
PROTEOMICS (2010)
Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF
Jennifer D. Lewis et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2009)
Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization
C. M. Haaland et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2009)
Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: Prolonged survival
Saied Mirshahidi et al.
VACCINE (2009)
Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52
Mona Shehata et al.
CLINICAL CANCER RESEARCH (2008)
Telomerase as a universal tumor antigen for cancer vaccines
Gregory L. Beatty et al.
EXPERT REVIEW OF VACCINES (2008)
Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity
Laura A. Payton et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
In vivo differentiation and genomic evolution in adult male germ cell tumors
J. E. Korkola et al.
GENES CHROMOSOMES & CANCER (2008)
Genomic copy number and expression patterns in testicular germ cell tumours
A. McIntyre et al.
BRITISH JOURNAL OF CANCER (2007)
DNA microarray analyses of melanoma gene expression: a decade in the mines
Keith S. Hoek
PIGMENT CELL RESEARCH (2007)
Ataxia telangiectasia-mutated gene is a possible biomarker for discrimination of infiltrative deep penetrating Nevi and metastatic vertical growth phase melanoma
Alexander Roesch et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
PrLZ is expressed in normal prostate development and in human prostate cancer progression
Ruoxiang Wang et al.
CLINICAL CANCER RESEARCH (2007)
The universal character of the tumour-associated antigen survivin
Mads Hald Andersen et al.
CLINICAL CANCER RESEARCH (2007)
Nuclear and cytoplasmic survivin: Molecular mechanism, prognostic, and therapeutic potential
Roland H. Stauber et al.
CANCER RESEARCH (2007)
Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: Identification of genetic indicators that predict patient outcome
Panayiotis Loukopoulos et al.
CANCER SCIENCE (2007)
Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52
Jennifer D. Lewis et al.
MOLECULAR CANCER RESEARCH (2007)
Telomerase-based immunotherapy of cancer
Erica L. Carpenter et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2006)
Molecular diagnosis of Burkitt's lymphoma
Sandeep S. Dave et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling
Michael Hummel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors
M. D. Landis et al.
ONCOGENE (2006)
Defining aggressive prostate cancer using a 12-gene model
Tarek A. Bismar et al.
NEOPLASIA (2006)
Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer
JA Byrne et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Tumor protein D52 (TPD52):: a novel B-cell/plasma-cell molecule with unique expression pattern and Ca2+-dependent association with annexin VI
E Tiacci et al.
BLOOD (2005)
Vaccination of cancer patients against telomerase induces functional antitumor CD8+T lymphocytes
RH Vonderheide et al.
CLINICAL CANCER RESEARCH (2004)
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer
MA Rubin et al.
CANCER RESEARCH (2004)
Tumor-associated antigens: From discovery to immunity
JD Lewis et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2003)
Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues
KS Wilson et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors
JR Pollack et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
